Compare Eos Energy Enterprises Inc (EOSE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Merck & Co., Inc. — how do they compare? Eos Energy Enterprises Inc trades at $4.23 (market cap $1.54B), while Merck & Co., Inc. trades at $131.62 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 208.9× Eos Energy Enterprises Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | MRK | |
|---|---|---|
Market Cap | $1.54B | $321.77B |
Sector | Energy | Health |
52-Week High | $19.19 | $131.84 |
52-Week Low | $3.14 | $77.60 |
Enterprise Value | $1.88B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.38, up 8.15% on the day, amid mixed technical signals and persistent fundamental challenges. The company reported a Q2 2026 loss of $1.20 per share, missing estimates, but revenue growth is accelerating, with 2026 revenue projected at $214 million. Negative profit margins and cash burn remain significant concerns, though analyst sentiment shows a mixed but cautious outlook with a consensus price target of $7.75.
The stock presents a high-risk opportunity driven by revenue growth potential in energy storage, but investors face substantial risks from continued losses, dilution, and competitive pressures. Upside depends on execution improving margins and achieving profitability, while downside risks include further earnings misses and liquidity challenges.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
